Compare GH & HST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GH | HST |
|---|---|---|
| Founded | 2011 | 1927 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.3B | 13.3B |
| IPO Year | 2018 | 1998 |
| Metric | GH | HST |
|---|---|---|
| Price | $94.00 | $19.64 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 20 | 13 |
| Target Price | ★ $117.80 | $18.81 |
| AVG Volume (30 Days) | 1.9M | ★ 7.9M |
| Earning Date | 05-11-2026 | 05-21-2026 |
| Dividend Yield | N/A | ★ 4.68% |
| EPS Growth | 6.74 | ★ 11.11 |
| EPS | N/A | ★ 1.10 |
| Revenue | $982,021,000.00 | ★ $5,387,000,000.00 |
| Revenue This Year | $29.73 | $0.44 |
| Revenue Next Year | $27.71 | $1.70 |
| P/E Ratio | ★ N/A | $18.47 |
| Revenue Growth | ★ 32.88 | N/A |
| 52 Week Low | $34.91 | $12.27 |
| 52 Week High | $120.74 | $21.00 |
| Indicator | GH | HST |
|---|---|---|
| Relative Strength Index (RSI) | 36.72 | 52.23 |
| Support Level | $54.39 | $16.99 |
| Resistance Level | $115.77 | $21.00 |
| Average True Range (ATR) | 6.12 | 0.61 |
| MACD | -1.26 | -0.04 |
| Stochastic Oscillator | 9.73 | 23.97 |
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Host Hotels & Resorts owns 80 predominantly urban and resort upper-upscale and luxury hotel properties representing nearly 43,000 rooms, mainly in the United States. Host recently sold off the company's interests in a joint venture owning a portfolio of hotels throughout Europe and also sold other joint ventures that owned properties in Asia and the United States. The majority of Host's portfolio operates under the Marriott and Starwood brands.